 AIM ImmunoTech Inc NYSE:AIM has announced that it is working towards filing an Investigational New Drug IND application with the US Food and Drug Administration FDA for its long COVID investigational drug Ampligen, partly based on positive early data from its ongoing clinical trial. The company said it had amended its ongoing FDA-authorized AMP-511 trial to enroll four post-COVID patients with new onset myalgic encephalomyelitischronic fatigue syndrome MECFS following acute COVID-19. 